Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia

The severe acute respiratory syndrome coronavirus (SARS-CoV-2) has become the cause of a worldwide pandemic, and its clinical infection course in patients with hematological malignancies may be severe. We performed a retrospective study on 188 chronic lymphocytic leukemia patients (CLL) with COVID-1...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-01, Vol.14 (3), p.558
Main Authors: Puła, Bartosz, Pruszczyk, Katarzyna, Pietrusza, Ewa, Morawska, Marta, Piszczek, Weronika, Kalicińska, Elżbieta, Szeremet, Agnieszka, Tryc-Szponder, Jagoda, Wąsik-Szczepanek, Ewa, Drozd-Sokołowska, Joanna, Krzemień, Helena, Rejus, Aleksandra, Gajewska, Małgorzata, Wiśniewski, Kamil, Wysocki, Maciej, Majeranowski, Alan, Paszkiewicz-Kozik, Ewa, Steckiewicz, Paweł, Szukalski, Łukasz, Bołkun, Łukasz, Długosz-Danecka, Monika, Giannopoulos, Krzysztof, Jamroziak, Krzysztof, Lech-Marańda, Ewa, Hus, Iwona
Format: Article
Language:English
Subjects:
Age
Antigens
CD20 antigen
Chronic infection
Chronic lymphocytic leukemia
Coronaviruses
COVID-19
Enzyme inhibitors
Fatalities
Hematology
Hemoglobin
Hospitalization
Infections
L-Lactate dehydrogenase
Lactic acid
Leukemia
Lymphatic leukemia
Multivariate analysis
Pandemics
Patients
Platelets
Protein-tyrosine kinase
Severe acute respiratory syndrome coronavirus 2
Survival
Survival analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The severe acute respiratory syndrome coronavirus (SARS-CoV-2) has become the cause of a worldwide pandemic, and its clinical infection course in patients with hematological malignancies may be severe. We performed a retrospective study on 188 chronic lymphocytic leukemia patients (CLL) with COVID-19 infection. At the time of infection 51 patients (27.1%) were treated with Bruton tyrosine kinase inhibitor (BTKi), 46 (24.5%) with anti-CD20 antibodies while 37 patients (19.7%) received venetoclax. In total, 111 patients (59.0%) required hospitalization and 50 patients (26.5%) died due to COVID-19. Patients with poor performance status (ECOG >1; = 0.02), advanced age (>65 years; = 0.04), low hemoglobin concentration (≤10 g/dl; = 0.0001), low platelets (
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14030558